The Cancer Genome Atlas links CYP4F22 overexpression to hepatocellular carcinomas (found in ∼60% of samples tested) and tumors of the bladder, breast and ovaries, however its role in cancer progression remains unclear [53]. This evidence concerns the gene CYP4F22 and hepatocellular carcinoma.